Virax successfully completes HIV clinical trial
28 November, 2002 by Melissa TrudingerVirax has announced the successful completion of its Phase I/IIa trial for its HIV immune-based therapeutic VIR201, with the last of 34 patients completing the six-month series of injections and blood tests.
MHRI research identifies targets for psychiatric disease
28 November, 2002 by Melissa TrudingerHigh-throughput screening techniques are being used in a unique approach to studying the molecular causes of schizophrenia and bipolar disorder.
IVF community doubts clone doctor claims
27 November, 2002 by Pete YoungAustralia's IVF community is deeply sceptical of claims by Italian embryologist Severino Antinori that the first birth of a cloned human embryo will take place in early January.
AustCancer miffed by market reaction
25 November, 2002 by Pete YoungCancer vaccine developer Australian Cancer Technology is mystified and disappointed by negative share market reaction to positive news from human trials of its cancer vaccine, Pentrix.
CSL celebrates cervical cancer vaccine success
21 November, 2002 by Graeme O'NeillCancer research is all hard slog, a long journey of many small steps, punctuated all too rarely by a genuine leap forward -- like the one announced today by CSL and its partner, pharma giant Merck and Co.
Sirtex moves toward US target
21 November, 2002 by Melissa TrudingerSirtex Medical is on track to achieve its goal of rolling out its SIR-Spheres cancer treatment in ten US hospitals by the end of the year, according to CEO Colin Sutton, with the ninth centre at Emory University Hospital treating its first two patients last week.
UTS brings in American to head infectious disease institute
19 November, 2002 by Graeme O'NeillThe University of Technology, Sydney (UTS) has appointed eminent American parasitologist Prof Michael Wallach as director of its new Institute for the Biotechnology of Infectious Diseases.
Research grant to help crystallise malaria mystery
18 November, 2002 by Pete YoungEncouraging results are flowing for Australian researchers using computer graphics to find inhibitors of a protein that plays a pivotal role in the life cycle of the parasite that causes malaria.
Cancer treatment targeted by new QIMR agreement
13 November, 2002 by Pete YoungGene discovery and drug development company diaDexus has signed a deal with the Queensland Institute for Medical Research (QIMR) concerning a novel molecule with potential for treating cancers in both males and females.
Monash pain research nets UK licensing deal
08 November, 2002 by Melissa TrudingerA new approach to treating pain has been licensed to British company RiboTargets by Monash University in a deal brokered by Victorian technology commercialisation company Biocomm.
Panbio moves into DNA diagnostics
05 November, 2002 by Pete YoungMedical diagnostics company Panbio Ltd, which has built its business around traditional microbiology kits, is moving into the fast-growing field of DNA probe-based diagnostics.
Gradipore says at AGM it will change
01 November, 2002 by David BinningHaving been promised the world, impatient shareholders of Sydney-based separations company Gradipore were demanding answers at Thursday's company AGM at the Australian Stock Exchange.
Medica achieves funding target in placement
30 October, 2002 by Melissa TrudingerMedica Holdings has raised $3.25 million in a private placement to leading Australian institutional investors.
Metabolic teams with BresaGen to produce anti-obesity compound
30 October, 2002 by Graeme O'NeillMelbourne biotechnology company Metabolic Pharmaceuticals has engaged Adelaide biotech BresaGen to develop a scaleable production system for its promising anti-obesity compound AOD9604.
Sirtex gains European approval
23 October, 2002 by Pete YoungAnti-cancer company Sirtex Medical has been given the green light to begin marketing and sales of its lead product SIR-Spheres in the European Community.
